Jack Kaye Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Jack Kaye.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Jack Kaye. Jack Kaye is Director in KERYX BIOPHARMACEUTICALS INC ($KERX) and Director in DYADIC INTERNATIONAL INC ($DIL) and Director in uniQure N.V. ($QURE).
Latest Insider Trading Transactions of Jack Kaye
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, DIL, KERX, QURE
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 04 2021 | QURE | uniQure N.V. | Kaye Jack | Director | Sell | S | 37.60 | 504 | 18,950 | 18,069 | 18.6 K to 18.1 K (-2.71 %) |
| Mar 01 2021 | QURE | uniQure N.V. | Kaye Jack | Director | Option Exercise | A | 37.00 | 4,107 | 151,959 | 4,107 | |
| Mar 01 2021 | QURE | uniQure N.V. | Kaye Jack | Director | Grant | A | 0.00 | 2,382 | 0 | 18,573 | 16.2 K to 18.6 K (+14.71 %) |
| Mar 02 2020 | QURE | uniQure N.V. | Kaye Jack | Director | Option Exercise | A | 51.81 | 3,620 | 187,552 | 3,620 | |
| Mar 02 2020 | QURE | uniQure N.V. | Kaye Jack | Director | Grant | A | 0.00 | 2,063 | 0 | 16,191 | 14.1 K to 16.2 K (+14.60 %) |
| Mar 02 2020 | QURE | uniQure N.V. | Kaye Jack | Director | Option Exercise | A | 51.81 | 3,620 | 187,552 | 3,620 | |
| Mar 02 2020 | QURE | uniQure N.V. | Kaye Jack | Director | Grant | A | 0.00 | 2,063 | 0 | 16,191 | 14.1 K to 16.2 K (+14.60 %) |
| Jan 30 2020 | QURE | uniQure N.V. | Kaye Jack | Director | Sell | S | 62.20 | 806 | 50,133 | 14,128 | 14.9 K to 14.1 K (-5.40 %) |
| Jan 03 2020 | DIL | DYADIC INTERNATION ... | Kaye Jack | Director | Option Exercise | A | 5.27 | 75,000 | 395,250 | 75,000 | |
| Jun 27 2019 | DIL | DYADIC INTERNATION ... | Kaye Jack | Director | Option Exercise | A | 5.83 | 25,000 | 145,750 | 25,000 | |
| Jan 31 2019 | QURE | uniQure N.V. | Kaye Jack | Director | Sell | S | 31.31 | 1,210 | 37,885 | 14,934 | 16.1 K to 14.9 K (-7.50 %) |
| Jan 31 2019 | QURE | uniQure N.V. | Kaye Jack | Director | Option Exercise | A | 31.71 | 5,295 | 167,904 | 5,295 | |
| Jan 31 2019 | QURE | uniQure N.V. | Kaye Jack | Director | Grant | A | 0.00 | 3,230 | 0 | 16,144 | 12.9 K to 16.1 K (+25.01 %) |
| Jan 31 2018 | QURE | uniQure N.V. | Kaye Jack | Director | Sell | S | 18.53 | 2,878 | 53,329 | 12,914 | 15.8 K to 12.9 K (-18.22 %) |
| Jan 30 2018 | QURE | uniQure N.V. | Kaye Jack | Director | Option Exercise | A | 19.39 | 6,390 | 123,902 | 6,390 | |
| Jan 30 2018 | QURE | uniQure N.V. | Kaye Jack | Director | Grant | A | 0.00 | 4,792 | 0 | 15,792 | 11 K to 15.8 K (+43.56 %) |
| Jan 31 2017 | QURE | uniQure N.V. | Kaye Jack | Director | Option Exercise | A | 0.00 | 11,000 | 0 | 11,000 | |
| Jan 31 2017 | QURE | uniQure N.V. | Kaye Jack | Director | Option Exercise | A | 5.37 | 11,000 | 59,070 | 11,000 | |
| Jun 18 2015 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Option Exercise | A | 9.95 | 30,000 | 298,500 | 30,000 | |
| Jun 18 2015 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Grant | A | 0.00 | 10,000 | 0 | 85,000 | 75 K to 85 K (+13.33 %) |
| Jun 26 2014 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Option Exercise | A | 15.04 | 30,000 | 451,200 | 30,000 | |
| Jun 26 2014 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Grant | A | 0.00 | 10,000 | 0 | 75,000 | 65 K to 75 K (+15.38 %) |
| Sep 09 2013 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Gift | G | 9.13 | 6,000 | 54,780 | 65,000 | 71 K to 65 K (-8.45 %) |
| Sep 09 2013 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Gift | G | 9.13 | 3,000 | 27,390 | 71,000 | 74 K to 71 K (-4.05 %) |
| Sep 09 2013 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Gift | G | 9.13 | 6,000 | 54,780 | 74,000 | 80 K to 74 K (-7.50 %) |
| Jun 21 2013 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Option Exercise | A | 8.24 | 25,000 | 206,000 | 25,000 | |
| Jun 21 2013 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Grant | A | 0.00 | 15,000 | 0 | 80,000 | 65 K to 80 K (+23.08 %) |
| Feb 15 2013 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Gift | G | 1.81 | 5,000 | 9,050 | 65,000 | 70 K to 65 K (-7.14 %) |
| Feb 15 2013 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Gift | G | 1.81 | 5,000 | 9,050 | 70,000 | 75 K to 70 K (-6.67 %) |
| Jun 22 2012 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Option Exercise | A | 1.80 | 25,000 | 45,000 | 25,000 | |
| Jun 22 2012 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Grant | A | 0.00 | 15,000 | 0 | 75,000 | 60 K to 75 K (+25.00 %) |
| Jan 04 2012 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Gift | G | 2.65 | 9,720 | 25,758 | 60,000 | 69.7 K to 60 K (-13.94 %) |
| Dec 19 2011 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Gift | G | 2.42 | 86,680 | 209,766 | 69,720 | 156.4 K to 69.7 K (-55.42 %) |
| Dec 08 2010 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Sell | S | 5.00 | 20,000 | 100,000 | 141,400 | 161.4 K to 141.4 K (-12.39 %) |
| Oct 01 2010 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Sell | S | 5.02 | 25,000 | 125,500 | 161,400 | 186.4 K to 161.4 K (-13.41 %) |
| Jun 18 2009 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Option Exercise | A | 1.05 | 10,000 | 10,500 | 10,000 | |
| Jun 18 2009 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Grant | A | 0.00 | 75,000 | 0 | 171,400 | 96.4 K to 171.4 K (+77.80 %) |
| Jun 20 2008 | KERX | KERYX BIOPHARMACEU ... | Kaye Jack | Director | Option Exercise | A | 0.48 | 10,000 | 4,800 | 10,000 |
Page: 1